The combination of BH3 mimetics targeting different anti-apoptotic proteins such as Bcl-2 and Mcl-1 or Bcl-xL and Mcl-1, has been reported to shown significant benefit for the treatment of melanoma [121]. This evidence concerns the gene BCL2 and melanoma.